Osalmid

Osalmid

SCHEMBL220088

O=C(Nc1ccc(O)cc1)c1ccccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 1.00
MEN1 O00255 5/20 0.79
KMT2A Q03164 5/20 0.79
TP53 P04637 4/20 0.79
HTT P42858 4/20 0.79
KDM4E B2RXH2 3/20 0.79
HSD17B10 Q99714 2/20 0.79
HPGD P15428 1/20 0.79
NPC1 O15118 4/20 0.74
RAB9A P51151 3/20 0.74
SMN1; SMN2 Q16637 2/20 0.74
POLB P06746 2/20 0.74
NFKB1 P19838 1/20 0.74
NFKB2 Q00653 1/20 0.74
RELA Q04206 1/20 0.74
PNLIP P16233 4/20 0.68
MAPT P10636 1/20 0.68
ALOX15 P16050 3/20 0.66
PLAU P00749 2/20 0.66
F2 P00734 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Osalmid SCHEMBL29928981 1.00 LMNA (1.00) LMNAMEN1KMT2ATP53HTT
Osalmid SCHEMBL28180566 0.95 LMNA (0.90) LMNAMEN1KMT2ATP53HTT
SCHEMBL18327174 0.94 LMNA (0.89) LMNAMEN1KMT2ATP53HTT
Osalmid SCHEMBL10526328 0.89 PNLIP (0.88) LMNAMEN1KMT2ATP53HTT
Salicylanilide SCHEMBL20165864 0.88 MEN1 (1.00) LMNAMEN1KMT2ATP53HTT
Salicylanilide SCHEMBL28262329 0.88 MEN1 (1.00) LMNAMEN1KMT2ATP53HTT
Salicylanilide SCHEMBL14051034 0.88 MEN1 (1.00) LMNAMEN1KMT2ATP53HTT
Salicylanilide SCHEMBL152221 0.88 MEN1 (1.00) LMNAMEN1KMT2ATP53HTT
Salicylanilide SCHEMBL5801955 0.86 MEN1 (0.96) LMNAMEN1KMT2ATP53HTT
Salicylanilide SCHEMBL2968865 0.86 MEN1 (0.96) LMNAMEN1KMT2ATP53HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 987 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026105442-A1 COATING FILM, ELECTRONIC DEVICE, MOBILE BODY, AND COATING LIQUID ハドラスホールディングス株式会社 2026-05-21 WO claimed
EP-3512821-B1 PROCESS FOR TREATING A SUBSTRATE MADE OF STONE MATERIAL ANTOLINI LUIGI & C S P A (IT) 2026-03-11 EP claimed
US-20250325701-A1 HIGH EFFICIENCY GENE DELIVERY SYSTEM HARVARD COLLEGE (US) 2025-10-23 US claimed
US-12322298-B2 Prosthesis simulator devices and methods GEORGIA TECH RESEARCH CORPORATION (US) 2025-06-03 US claimed
CN-119799332-A Linear polarization low-threshold polarization laser source capable of being processed by solution and preparation method thereof 山东大学 2025-04-11 CN claimed
CN-119673310-A Accounting method for water drainage and contribution of nitrogen and phosphorus into river/lake of large lake region polder 中国科学院南京地理与湖泊研究所 2025-03-21 CN claimed
CN-119598908-A Turbidity simulation method, equipment and program for composite drainage basin in hilly-plain polder area 中国科学院南京地理与湖泊研究所 2025-03-11 CN claimed
CN-116948642-B Nano structure for enhancing nonlinear luminescence performance of perovskite and preparation method thereof 东南大学 2025-03-04 CN claimed
EP-4476217-A1 MORPHIC FORMS OF CFT7455 AND METHODS OF MANUFACTURE THEREOF C4 Therapeutics, Inc. (US) 2024-12-18 EP claimed
CN-118993741-A Polymer precursor ceramic film and cutting force sensor 郑州大学 2024-11-22 CN claimed
US-20120010284-A1 CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS BEZWADA BIOMEDICAL, LLC (US) 2012-01-12 US claimed
US-20110212927-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME NEUROGESX, INC. (US) 2011-09-01 US claimed
CN-102149282-A Carbonate prodrugs and methods of using the same NEUROGESX INC 2011-08-10 CN claimed
EP-2291084-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME Neurogesx, Inc. (US) 2011-03-09 EP claimed
WO-2009143297-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME NEUROGESX, INC. (US) 2009-11-26 WO claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-5811547-A Method for inducing crystalline state transition in medicinal substance NIPPON SHINYAJU CO., LTD. (JP) 1998-09-22 US claimed
EP-0046270-B1 NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM INTERx RESEARCH CORPORATION (US) 1986-05-21 EP claimed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212927-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME CA6, CA7, CA4 LMNA 2401/4885MEN1 691/4885KMT2A 2173/4885
US-20120010284-A1 CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS MME, AADAC, LGMN LMNA 1047/4885MEN1 1159/4885KMT2A 4540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.